Compare DAC & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | GRDN |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Retail-Drug Stores and Proprietary Stores |
| Sector | Consumer Discretionary | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2006 | 2024 |
| Metric | DAC | GRDN |
|---|---|---|
| Price | $99.50 | $29.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $105.00 | $33.33 |
| AVG Volume (30 Days) | 69.6K | ★ 273.4K |
| Earning Date | 02-09-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 25.05 | 0.28 |
| Revenue | $1,034,370,000.00 | ★ $1,389,638,000.00 |
| Revenue This Year | N/A | $19.50 |
| Revenue Next Year | N/A | $0.48 |
| P/E Ratio | ★ $4.01 | $108.08 |
| Revenue Growth | 2.90 | ★ 18.68 |
| 52 Week Low | $65.40 | $17.78 |
| 52 Week High | $102.20 | $37.43 |
| Indicator | DAC | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 68.57 | 45.65 |
| Support Level | $97.82 | $30.17 |
| Resistance Level | $102.20 | $31.90 |
| Average True Range (ATR) | 1.82 | 1.29 |
| MACD | 0.58 | -0.16 |
| Stochastic Oscillator | 80.81 | 36.03 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.